Heparin News and Research

RSS

Heparin, a highly-sulfated glycosaminoglycan, is widely used as an injectable anticoagulant, and has the highest negative charge density of any known biological molecule. It can also be used to form an inner anticoagulant surface on various experimental and medical devices such as test tubes and renal dialysis machines. Pharmaceutical grade heparin is derived from mucosal tissues of slaughtered meat animals such as porcine (pig) intestine or bovine (cow) lung.

PolyMedix Phase 1B/2 clinical study data presented at ATVB meeting

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, announced that clinical data with PMX-60056 were presented at the American Heart Association's Arteriosclerosis, Thrombosis, and Vascular Biology Meeting in Chicago on April 28, 2011.

4 May 2011

Desirudin more effective for VTE prevention in patients with renal impairment

Desirudin reduced major venous thromboembolism and post-operative bleeding compared with the standard of care, enoxaparin, in patients with poor kidney function undergoing orthopedic surgery, according to a poster presented at the Arteriosclerosis, Thrombosis and Vascular Biology meeting.

3 May 2011

PolyMedix defensin-mimetic antibiotic compounds show antimicrobial efficacy against anthrax

PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat patients with acute infectious diseases and cardiovascular disorders, announced today that several of its defensin-mimetic antibiotic compounds have shown antimicrobial efficacy in an animal model against the bacteria that causes anthrax.

26 Apr 2011

New nano-systems capable of binding heparin as effectively as protamine

New nano-systems developed in York may eventually help patients recover from surgery without the danger of allergic reactions to drugs.

26 Apr 2011

Bayer's oral contraceptives may increase risk of blood clots, stroke or heart attack

Bayer HealthCare Pharmaceuticals, Inc. is aware of two studies published today in The British Medical Journal, ONLINE FIRST.

25 Apr 2011

Patients with heart failure can benefit from left ventricular assist device

Non-cardiac surgery can be performed safely in patients with a heart device typically implanted into patients waiting for a transplant, according to a study at Henry Ford Hospital in Detroit.

15 Apr 2011

RE-LY trial results suggest Pradaxa capsule reduces risk of stroke in AF patients

Two new retrospective subanalyses of the RE-LY trial, involving Pradaxa capsules, suggested that the reduction in stroke risk achieved with PRADAXA 150mg over warfarin occurred irrespective of CHA2DS2-VASc risk score and the type of non-valvular atrial fibrillation.

5 Apr 2011

Regado's REG1 system Phase 2b trial results presented at i2 Summit

Regado Biosciences, Inc., a privately held company pioneering the development of antithrombotic aptamers with active control agents, announced today the primary results of the RADAR Phase 2b clinical trial of the company's lead product, the anticoagulation system REG1, at the i2 Summit during the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans, LA.

4 Apr 2011

Allscripts ED 7.0 receives Complete EHR certification

Allscripts announced today that Allscripts ED™ 7.0, the company's standalone Emergency Department Information System (EDIS), is 2011/2012 compliant and was certified as a Complete EHR on March 2, 2011 by the Certification Commission for Health Information Technology, an ONC-ATCB, in accordance with the applicable hospital certification criteria adopted by the Secretary of Health and Human Services.

30 Mar 2011

Regado to present REG1 Phase 2b trial results against acute coronary syndromes at i2 Summit

Regado Biosciences, Inc., a privately held company pioneering the development of antithrombotic aptamers with active control agents, announced that Thomas J. Povsic, MD, PhD, Assistant Professor of Medicine at Duke University, will present results of the RADAR Phase 2b clinical trial for the Company's lead product, the REG1 anticoagulation system, at the i2 Summit during the American College of Cardiology 2011 60th Annual Scientific Session & Expo.

29 Mar 2011

Study finds increased risk of VTE during first year of combination oral contraceptive usage

Bayer HealthCare Pharmaceuticals Inc. today announced that interim results from a large, prospective, observational cohort safety study offer insights into the increased risk of venous thromboembolism (VTE), or blood clots, which is a well-established risk in women who use combination oral contraceptives (COCs), also known as "the Pill".

25 Mar 2011

First clinical use of GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface on lower profile delivery system

W. L. Gore & Associates (Gore) today reported the first clinical use in the U.S. of the GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface on a lower profile delivery system. The GORE VIABAHN Device is designed to percutaneously treat Superficial Femoral Artery (SFA) and iliac peripheral artery disease by relining the native vessel.

21 Mar 2011

Excelsior medical's SwabFlush receives FDA 510(k) clearance

Excelsior Medical Corporation announced today that it has received FDA 510(k) clearance for SwabFlush™, its latest product for the vascular access and infection control markets.

8 Mar 2011

Study: Heparin plays a key role in mast cell-driven allergic and inflammatory reactions

Heparin plays a key role in allergic and inflammatory reactions driven by mast cells, scientists from Karolinska Institutet in Sweden shows in an international collaboration involving colleagues from Germany and Switzerland. The study is published in the recent issue of Immunity, and sheds some new light on the biological function of heparin.

25 Feb 2011

PolyMedix completes PMX-30063 Phase 1 exposure-escalation clinical study to treat Staph infections

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, today announced the successful completion of a Phase 1 exposure-escalation clinical study with its synthetic defensin-mimetic antibiotic, PMX-30063.

24 Feb 2011

GORE PROPATEN Vascular Graft for hemodialysis access receives CE Mark approval

W. L. Gore & Associates announced the GORE PROPATEN Vascular Graft for hemodialysis access has received CE Mark. Arteriovenous Grafts are used to create a conduit for repeated blood access during hemodialysis, allowing blood to be withdrawn from the body and cleansed when a patient has End Stage Renal Disease, commonly referred to as kidney failure.

22 Feb 2011

FDA approves GORE VIABAHN device to treat peripheral artery disease

W. L. Gore & Associates today announced it has received FDA approval for the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface on a lower profile delivery system.

17 Feb 2011

Neurologic and neurosurgical patients do not receive therapy to prevent VTE: Study

Patients with strokes, brain tumors and spinal cord injuries are at high risk for life-threatening blood clots, but many do not receive preventive therapy, Loyola University Health System researchers report.

14 Feb 2011

Luciferase enzyme offers promise for improved monitoring of heparin therapy: New study

The enzyme that makes fireflies glow is lighting up the scientific path toward a long-sought new medical imaging agent to better monitor treatment with heparin, the blood thinner that millions of people take to prevent or treat blood clots, scientists are reporting. Their study appears in the ACS' monthly journal Bioconjugate Chemistry.

10 Feb 2011

PolyMedix commences PMX-60056 Phase 2 clinical trial in patients undergoing PCI

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has initiated a Phase 2 clinical trial, following conclusion of a review by the United States Food and Drug Administration (FDA) of a protocol submitted by PolyMedix, to assess the safety and efficacy of its heptagonist, PMX-60056, in reversing heparin in patients undergoing Percutaneous Coronary Intervention (PCI) procedures.

9 Feb 2011